

## **A clinical trial evaluating a new treatment for PH is now open for enrollment**

A Phase III trial evaluating the effectiveness and safety of *Oxalobacter formigenes* treatment in patients with Primary Hyperoxaluria (PH), is now actively recruiting patients in the USA and Europe.

*Oxalobacter formigenes* is a unique oxalate degrading bacteria naturally present in the intestine of 50-70% of the general population. This bacterium uses only oxalate as its energy source and therefore it efficiently degrades oxalate. When *Oxalobacter formigenes* is taken, the oxalate degrading bacteria are released into the intestine where they continuously degrade oxalate. This excessive break down of oxalate in the intestine may help dissolve the extra oxalate being produced by the liver in patients with PH. If the bacterium can do this, less oxalate will be filtered through the kidneys into the urine.

Participants in this study will receive *Oxalobacter formigenes* or a placebo. The duration of the study is approximately 6 months and the study medication is given orally twice a day. Eligibility for this study will be determined at the study center. If you or your child has PH and are at least 2 years old and interested in participating in this trial, please contact (or ask your doctor to contact) the clinical trial center closest to you.

For further information on the trial follow this link to ClinicalTrial.gov:

<http://www.clinicaltrial.gov/ct2/show/NCT01037231?term=oxalobacter&rank=1>

### **If you are from the USA please contact:**

**Mayo Clinic** (Department of Pediatric Nephrology)

Rochester, Minnesota

**Principal Investigator:** Dawn Milliner, MD

**Contact:** Chuck Madsen:

E-mail: [Madsen.charles@mayo.edu](mailto:Madsen.charles@mayo.edu)

Phone: (507) 266 9391

### **If you are from Europe please contact:**

**University Children's Hospital** (Division of Pediatric Nephrology)

Cologne

**Principal Investigator:** Bernd Hoppe, MD

**Contact:** Bernd Hoppe, MD:

E-mail: [bernd.hoppe@uk-koeln.de](mailto:bernd.hoppe@uk-koeln.de)

**Academy Medical Center, University of Amsterdam** (Division of Pediatric Nephrology)

Amsterdam

**Principal Investigator:** Jaap Groothoff MD

**Contact:** Jasper Jöbsis:

E-mail: [j.j.jobsis@amc.uva.nl](mailto:j.j.jobsis@amc.uva.nl)

